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Dialysis patients have a high risk of cardiovascular disease.
Cardiac rehabilitation is recommended in the general
population as a standard component of care and covered by
Medicare for those who have undergone coronary artery
bypass grafting (CABG). Here we determined the impact of
cardiac rehabilitation on Medicare expenditures and its cost
effectiveness in dialysis patients. A cohort of 4,324 patients
with end-stage renal disease who began chronic
hemodialysis and had undergone CABG over a seven year
period were selected from the United States Renal Data
System. Cardiac rehabilitation was defined by Current
Procedural Terminology codes for monitored and
non-monitored exercise in Medicare claims data. Medicare
expenditures included in and outpatient claims adjusted to
1998 dollars. Over a 42-month follow-up, cardiac
rehabilitation at baseline was associated with higher
cumulative Medicare expenditures but this increase was not
statistically significant. During the same period, cardiac
rehabilitation was significantly associated with longer
cumulative life, having an incremental benefit of 76 days.
The incremental cost-effectiveness ratio of $13,887 per year
of life saved suggests that cardiac rehabilitation is highly
cost-effective in patients with end-stage renal disease
following CABG.
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In 2005, there were approximately 485,000 end-stage renal
disease (ESRD) patients in the United States, for whom total
Medicare costs reached 21.3 billion dollars.1 Given this
economic burden, cost evaluation of medical therapies, in
addition to standard effectiveness and safety assessment, is
increasingly important for policy-makers and third-party
payers.
The leading cause of death among dialysis patients is
cardiovascular disease (CVD), with cardiovascular mortality
almost 40 times that in the general population.2 For patients
having experienced coronary events, cardiac rehabilitation is
considered an integral part of the contemporary care.3,4
Medicare covers cardiac rehabilitation for patients who have
undergone coronary artery bypass grafting (CABG) and for
patients who have had an acute myocardial infarction (AMI)
in the past 12 months or have stable angina.5 In the general
population, cardiac rehabilitation has been shown to reduce
coronary heart disease risk factors6 and mortality from
coronary heart disease.7–11 Furthermore, a limited number of
studies have suggested that it is cost effective and even cost
saving.12–15
CABG may confer a lowered risk for death in dialysis
patients compared with no revascularization. In an earlier
report, we investigated the characteristics and long-term
survival of dialysis patients who received cardiac rehabilita-
tion after CABG, using United States Renal Data System files
linked with Medicare inpatient and outpatient claims.16 We
found that patients who received cardiac rehabilitation after
CABG, compared to those who did not, had significantly
improved survival. The purpose of this study was to assess
the impact of dialysis patients’ receipt of cardiac rehabilita-




A total of 6040 eligible ESRD patients who initiated chronic
hemodialysis (HD) and underwent CABG between 1998 and
2004 were identified from United States Renal Data System
database. Of them, 635 patients were excluded because of
being nonambulatory, having extended hospital stays for the
CABG procedure, or incurring excessive Medicare expendi-
ture during a 6-month entry period. In addition, 1081
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patients were dropped from the study cohort as being in the
lowest propensity quintile for receiving cardiac rehabilitation
at baseline. See Materials and Methods section for details of
these exclusion criteria. The final study cohort consisted of
4324 patients.
Baseline demographic and clinical characteristics of the
4324 patients are reported in Table 1. A propensity score
(C-index, 0.65) was calculated for receiving cardiac rehabi-
litation at baseline, and Table 1 is summarized by the cardiac
rehabilitation status and the propensity score quartiles. Of
the study cohort, 68% were 65 years of age or older, 72%
were men, and 81% were white. Approximately 16.4%
received cardiac rehabilitation in a period between CABG
surgery and 6 months after CABG hospitalization discharge.
The cardiac rehabilitation and noncardiac rehabilitation
groups as a whole were fairly different in their baseline
characteristics. However, these differences were minimized
after stratification by the propensity score quartiles.
Long-term cost and effectiveness of receiving cardiac
rehabilitation
The follow-up of this study started 6 months after CABG
hospitalization discharge. The mean follow-up time of the
study cohort was 20.3 months, and 43.6% died or achieved
42 months of follow-up. The censoring was because of either
the end of follow-up as of 31 December 2004 or renal
transplantation; about 6% of the study cohort had renal
transplantation during the 42-month follow-up period. The
overall survival rate was 45.0% at 42 months. Cumulative
Medicare expenditure and cumulative lifetime at 42 months
were used as the primary cost and effectiveness outcomes,
respectively. A cumulative measure at a follow-up time is the
measure accumulated up to death or the follow-up time,
whichever occurs earlier. The estimated mean cumulative
Medicare expenditure and lifetime at 42 months for the study
cohort were $105,133 and 29.8 months, respectively.
Table 2 provides estimated covariate effects on cumulative
Medicare expenditure and lifetime at 42 months, from
multivariate regression models with stratification by the
propensity score quartiles. Cardiac rehabilitation at baseline
was associated with higher cumulative Medicare expenditure
at 42 months, with an increase of $2904 (95% confidence
interval (CI): 7028, 11,940), but this increase was not
statistically significant. At the same time, cardiac rehabilita-
tion at baseline was significantly associated with longer
cumulative lifetime with an increase of 76 days (95% CI: 22,
129). The estimated incremental cost-effectiveness ratio was
$13,887 per year of life saved at 42 months. Among other
baseline measures included in the models, older patient age
(4¼ 65), male gender, and vintage were significantly
associated with both shorter survival time and lower
Medicare expenditure, whereas initial Medicare expenditure
was significantly associated with shorter survival and higher
Medicare expenditure. Number of cardiovascular conditions
and chronic obstructive pulmonary disease (COPD) at HD
start were significantly associated with shorter survival,
whereas Asian race (relative to white) was significantly
associated with longer survival. Finally, black race (relative to
white), Medicaid coverage, higher serum albumin, primary
diagnosis of diabetes, and AMI before CABG were signifi-
cantly associated with higher Medicare expenditure at 42
months.
Table 1 | Characteristics of the study cohort
Propensity score quartile
First Second Third Fourth
P-value
Cardiac rehabilitation (yes/no) Y N Y N Y N Y N
Size 79 1001 147 934 194 888 287 794
Age X65 years (%) 57 67 68 69 75 68 72 67 0.18
Male (%) 39 50 73 69 82 78 91 93 0.90
Race (%) 1.00
Asian 6 5 3 3 2 2 0 0
Black 37 30 16 16 4 7 2 2
Native American 1 2 1 2 3 1 1 2
White 56 63 79 78 91 89 96 96
Other 0 0 1 1 0 0 0 0
Medicaid coveragea (%) 33 29 14 15 5 5 0 1 0.98
No. of cardiovascular conditionsa (mean) 1.2 1.4 1.4 1.3 1.4 1.3 1.3 1.2 0.45
Hemoglobina (g/100 ml; mean) 9.7 9.8 10.1 9.9 10.0 10.0 10.0 10.1 0.97
Serum albumina (g/100 ml; mean) 3.1 3.1 3.1 3.1 3.2 3.2 3.3 3.3 0.73
Diabetic ESRDa (%) 61 57 56 55 49 47 30 35 0.86
AMI before CABG (%) 41 50 43 42 35 36 21 20 0.69
COPDa (%) 6 8 12 8 5 9 8 7 0.88
Vintage (months; mean) 17.4 13.8 13.0 14.5 12.3 14.4 14.4 15.1 0.29
Hospital stays after CABG (days; mean) 14.4 16.7 14.0 13.8 12.9 12.6 9.7 9.5 0.83
Discharge to self-care/outpatient (%) 35 35 46 42 49 52 59 56 0.53
Initial Medicare expenditureb ($; mean) 26,579 27,341 24,797 24,714 18,729 19,283 14,736 14,551 0.69
ESRD, end-stage renal disease; CABG, coronary artery bypass grafting; HD, hemodialysis; AMI, acute myocardial infarction; COPD, chronic obstructive pulmonary disease.
aMeasured at HD start.
bAccumulated during the 6-month entry period.
A total of 4324 HD patients with CABG surgery as selected on the basis of baseline measures.
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To investigate the temporal trend of differences between
the cardiac rehabilitation and noncardiac rehabilitation
groups, the same models were applied to cumulative
Medicare expenditure and lifetime at 6, 12, 18, 24, 30, and
36 months. The regression coefficients of cardiac rehabilita-
tion along with their 95% CIs are plotted in Figure 1. The
differences in both cumulative Medicare expenditure and
lifetime were small during the first year. The survival benefit
of cardiac rehabilitation increased steadily over time, reach-
ing statistical significance after month 30. Meanwhile, by
month 36, the cardiac rehabilitation group showed a
statistically nonsignificant increase in cumulative Medicare
expenditure.
DISCUSSION
The estimated incremental cost-effectiveness ratio value for
receiving cardiac rehabilitation at baseline was $13,887 per
year of life saved among dialysis patients over a time horizon
of 42 months. Although there is no universally accepted
benchmark for the ‘cost-effective’ incremental cost-effective-
ness ratio value, a familiar categorization scheme designates a
value of $20,000 or less as highly cost effective, $20,000 to
$40,000 as cost effective, $40,000 to $60,000 as borderline
cost effective, and $60,000 or more as expensive.17–19 In this
realm, cardiac rehabilitation is regarded as highly cost
effective in our dialysis population under investigation.
To perform cost-effectiveness analysis, we adopted an
approach to the analysis of survival time different from that
in our previous investigation.16 The propensity score was
used in the current analysis to define the study cohort and to
conduct stratified analysis. In addition, the main survival
time outcome was cumulative lifetime at 42 months and the
multivariate linear regression model was adopted here,
whereas the Cox proportional hazards model was employed
in the previous investigation. Nevertheless, both analyses
were highly consistent in showing that receiving cardiac
rehabilitation was significantly associated with longer survi-
val time in dialysis patients after CABG.
Table 2 | Multivariate linear regression models predicting cumulative Medicare expenditure and cumulative lifetime at
42 months of 4324 HD patients with CABG surgery
Medicare expenditure ($) Lifetime (days)
Risk factor at baseline Estimate 95% CI Estimate 95% CI
Age X65 years 22,454 32,978 12,775 98 144 51
Male gender 15,498 25,345 6636 53 107 5
Race (reference=white)
Asian 22,908 14,968 55,130 116 3 214
Black 18,683 4394 32,119 34 38 100
Native American 3844 24,745 34,533 89 45 201
Other 40,574 41,705 65,778 264 582 491
Medicaid coveragea 21,564 6100 35,780 28 49 100
No. of cardiovascular conditionsa 1406 4274 1052 26 42 11
Hemoglobina 486 2861 1726 6 17 5
Serum albumina 6346 390 11,698 16 15 48
Diabetic ESRDa 11,623 3284 19,771 25 19 68
AMI before CABG 9179 607 17,198 6 38 47
COPDa 130 10,790 11,319 76 146 1
Vintage 600 843 327 9 11 7
Hospital stays after CABG 336 1022 283 2 6 2
Percentile of initial Medicare expenditureb 47,437 28,687 66,159 236 336 139
Discharge to self care/outpatient 1516 6483 9048 18 18 56
Cardiac rehabilitation 2904 7028 11,940 76 22 129
CABG, coronary artery bypass grafting; HD, hemodialysis; ESRD, end-stage renal disease; AMI, acute myocardial infarction; COPD, chronic obstructive pulmonary disease.
aMeasured at HD start.
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Figure 1 | Estimated differences and their 95% confidence
intervals between the cardiac rehabilitation group and
noncardiac rehabilitation group in cumulative Medicare
expenditure and cumulative lifetime.
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Our study suggested a moderate increment in cumulative
Medicare expenditure at 42 months associated with receiving
cardiac rehabilitation. However, this increment was not likely
because of the cardiac rehabilitation cost. By the start of
follow-up, most baseline cardiac rehabilitation sessions were
complete. Also, Figure 1 shows that the difference in
cumulative Medicare expenditure between the cardiac
rehabilitation and noncardiac rehabilitation groups was small
during the first year. Repeating our analysis by considering
hospitalization expenditure only (data not shown), we found
that the increment of cumulative hospitalization expenditure
was similar to that of cumulative Medicare expenditure in the
cardiac rehabilitation group.
Economic evaluations of cardiac rehabilitation have been
limited even in the general population.20,21 Data have
supported cost effectiveness of cardiac rehabilitation, with
increased cost per year of life saved comparing favorably with
other currently funded interventions. The majority of these
investigations focused on patients who have had myocardial
infarction. The strength of our study lies in the large
population-based sample of dialysis patients who were
followed for an extended period of time after CABG.
Nevertheless, it is also important to recognize several
potential limitations of this investigation. First, large
differences in baseline characteristics were observed between
patients who received cardiac rehabilitation and those who
did not. We made extensive efforts to address this imbalance
by adopting propensity score and multivariate regression
analysis. Nevertheless, as with any observational studies,
imbalance could still exist in unobserved patient character-
istics that might account for the expenditure and survival
differences.
Second, our results were based on, and therefore applied
to, healthier patients in the chronic HD population who
underwent CABG. The observed rate of receiving cardiac
rehabilitation among dialysis patients, approximately 13%,
was lower than the estimated rate of approximately 23% in
the general population after CABG.16 The cardiac rehabilita-
tion rate for less healthy subgroups of chronic HD patients
was even lower, and these subgroups were excluded from this
investigation.
Third, the time horizon for this study was 42 months after
the 6-month entry period following CABG hospitalization
discharge. As in any study with limited follow-up, the
increments of cumulative Medicare expenditure and
lifetime might not be the same when the time horizon is
extended.
At the same time, the findings of our study are
consistent with literature in the general population that
supports the efficacy and cost effectiveness of cardiac
rehabilitation. It is likely that core aspects of cardiac
rehabilitation services would be beneficial for virtually
all patients with cardiovascular disease. In conclusion,
this observational study suggests that cardiac rehabilitation




The data used in this analysis came from linking United States Renal
Data System files to Medicare inpatient and outpatient claims. The
former contained demographic and clinical information of dialysis
patients. Medicare primary-pay ESRD patients who initiated
chronic HD and underwent CABG while on chronic dialysis during
the period between 1 January 1998 and 31 December 2004 were
identified retrospectively from the United States Renal Data System
database. For patients who were younger than 65 years, only those
with CABG procedure dates that occurred day 90 or later of ESRD
were included, because many of these patients did not become
eligible for Medicare for up to 90 days after initiating dialysis and
therefore might not have complete claims data. In addition, we did
not include patients who, after the CABG procedure, left the
hospital against medical advice or were discharged to home under
care of an i.v. therapy provider or to hospice care.
A preliminary investigation of this study cohort showed that less
than 13% of CABG survivors received cardiac rehabilitation, and the
rate varied substantially across subgroups. Those subgroups with
minimal rate would provide little information on the association of
cardiac rehabilitation with Medicare expenditure and survival. For
this reason, we excluded the following patients: (1) patients who
were nonambulatory at dialysis initiation, (2) patients whose CABG
hospitalization exceeded 44 days following the surgery, or (3)
patients who incurred Medicare expenditure of over $66,244 during
the 6-month entry period. The cutoff points for the hospital stays
and initial Medicare expenditure were determined as the 99th
percentiles among patients who received cardiac rehabilitation at
baseline. Physical limitation might be the main reason for the
observed low rehabilitation rate among nonambulatory patients.
Patients with longer hospital stays for the CABG procedure or with
higher initial Medicare expenditure were more likely to experience
serious complications post-surgery; they were overly represented
among those who did not receive cardiac rehabilitation. After
applying these exclusion criteria, a propensity score for receiving
cardiac rehabilitation was calculated, and the patients in the lowest
quintile of the propensity score distribution were excluded as well.
Study design
The objective of this study was to assess the association between
receiving cardiac rehabilitation at baseline and cumulative Medicare
expenditure and survival time during a follow-up period of up to 42
months. The follow-up started after a 6-month entry period
following the discharge from CABG hospitalization to allow for
the determination of receiving cardiac rehabilitation at baseline. By
design, all patients included in the analysis survived at least 6
months after discharge from CABG hospitalization. Medicare
expenditure and survival time were followed up to 31 December
2004. A patient undergoing renal transplantation was treated as
being censored at the time of transplantation.
Measures
Cardiac rehabilitation was defined as outpatient cardiac rehabilita-
tion without or with continuous electrocardiogram monitoring
(Current Procedural Terminology codes 93797 and 93798).
Medicare covers participation by eligible patients in a cardiac
rehabilitation exercise program for up to 36 sessions, with three
sessions a week in a single 12-week period of therapy. For this
analysis, cardiac rehabilitation received after CABG and before the
end of the 6-month entry period was regarded as cardiac
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rehabilitation at baseline. This time period included about 90% of
the patients in our study population who ever received cardiac
rehabilitation.
Demographic characteristics of the patients included age, gender,
and race. Medicaid coverage at dialysis initiation (yes/no) was used
as an indicator of socioeconomic status (Medicaid is a federal/state
health insurance entitlement program for low-income people).
Clinical characteristics documented at dialysis initiation included
primary diagnosis of diabetes, number of existing cardiovascular
conditions (congestive heart failure, coronary artery disease, history
of AMI, cardiac arrest, dysrhythmia, cerebral vascular disease,
peripheral vascular disease), COPD, serum albumin (g/100 ml), and
hemoglobin (g/100 ml). After dialysis initiation, AMI that occurred
before CABG was also determined.
Medicare expenditures included claims from institutional and
physician/supplier data files. All costs were adjusted to 1998 dollars,
using the Medical Care component of the Consumer Price Index for
inflation. In addition, all cost value was discounted at an annual rate
of 3%.
Statistical analyses
The receipt of cardiac rehabilitation was not randomly determined
in this investigation, as with any observational study. In fact,
substantial clinical and socioeconomic differences between patients
who received cardiac rehabilitation at baseline and those who did
not were observed. Inadequately accounting for these differences
could lead to biased assessment of the effect of cardiac rehabilita-
tion. We employed the propensity score method22,23 to exclude
subgroups of patients with minimal propensity for receiving cardiac
rehabilitation and to carry out propensity score-stratified analyses.
Stepwise logistic regression was used to compute the propensity
score for receiving cardiac rehabilitation. Baseline measures used as
candidate covariates included demographic characteristics (age,
gender, race, and Medicaid coverage), clinical characteristics at the
dialysis initiation (number of cardiovascular conditions, hemoglo-
bin, serum albumin, primary diagnosis of diabetes, COPD), and
before CABG (AMI), as well as measures associated with the CABG
procedure (vintage defined as the dialysis duration at the time of
CABG, hospital stays after CABG, discharge destination of the
CABG hospitalization), and the decile ranking of Medicare
expenditure during the 6-month entry period. After the patients
in the lowest quintile of the estimated propensity score were
excluded, the same stepwise logistic regression was re-run to refine
the propensity scores for the study cohort. The refined propensity
score was used in the subsequent stratified analyses.
Demographic and baseline clinical characteristics were summar-
ized using means for continuous variables and percentages for
discrete variables, by the status of receiving cardiac rehabilitation at
baseline and by the propensity score quartiles. Comparisons, as
stratified by the propensity score quartiles, were made between
cardiac rehabilitation and noncardiac rehabilitation groups, using
linear regression for continuous variables and the Cochran–Man-
tel–Haenszel test for discrete variables.
A multivariate linear regression model was used to examine the
association between receiving cardiac rehabilitation at baseline and
cumulative Medicare expenditure during the follow-up. Other
dependent variables incorporated for adjustment included
demographic characteristics and baseline clinical characteristics as
well as percentiles of the entry-period Medicare expenditure. The
analysis was stratified by the propensity score quartiles, that is,
stratum-specific intercepts being incorporated in the model. To
accommodate censoring because of either renal transplantation or
the end of follow-up, we used a Horvitz–Thompson type approach
to missing data.24,25 An important component of this approach was
to estimate the probability of being censored for every uncensored
observation in the sample. A proportional hazards model was
employed for the censoring time with all the aforementioned
dependent variables. Subsequently, the uncensored observations,
each weighted inversely by its associated probability, formed a
pseudosample of complete cases to which the linear regression
model could be applied. To carry out further cost-effectiveness
analysis, a similar multivariate linear regression model coupled with
the Horvitz–Thompson approach was employed for cumulative
lifetime. For inference with these models, bootstrap of size 1000 was
used to construct 95% percentile CIs. The incremental cost-
effectiveness ratio was calculated for the cost-effectiveness assess-
ment of receiving cardiac rehabilitation at baseline after CABG.
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